CN108289905A - 用于癌症疗法的阿糖胞苷缀合物 - Google Patents

用于癌症疗法的阿糖胞苷缀合物 Download PDF

Info

Publication number
CN108289905A
CN108289905A CN201680070972.5A CN201680070972A CN108289905A CN 108289905 A CN108289905 A CN 108289905A CN 201680070972 A CN201680070972 A CN 201680070972A CN 108289905 A CN108289905 A CN 108289905A
Authority
CN
China
Prior art keywords
acid
subject
administered
compound
astarabine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680070972.5A
Other languages
English (en)
Chinese (zh)
Inventor
斯泰拉·甘格里诺维奇
鲁思·本亚喀尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bei O Seet Co Ltd
Original Assignee
Bei O Seet Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bei O Seet Co Ltd filed Critical Bei O Seet Co Ltd
Publication of CN108289905A publication Critical patent/CN108289905A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CN201680070972.5A 2015-12-03 2016-01-25 用于癌症疗法的阿糖胞苷缀合物 Pending CN108289905A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262428P 2015-12-03 2015-12-03
US62/262,428 2015-12-03
PCT/IL2016/050077 WO2017093993A1 (en) 2015-12-03 2016-01-25 Cytarabine conjugates for cancer therapy

Publications (1)

Publication Number Publication Date
CN108289905A true CN108289905A (zh) 2018-07-17

Family

ID=58796462

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680070972.5A Pending CN108289905A (zh) 2015-12-03 2016-01-25 用于癌症疗法的阿糖胞苷缀合物

Country Status (10)

Country Link
US (1) US11058701B2 (https=)
EP (1) EP3383407B1 (https=)
JP (3) JP7149183B2 (https=)
CN (1) CN108289905A (https=)
AU (2) AU2016362830B2 (https=)
BR (1) BR112018011177A2 (https=)
CA (1) CA3007058C (https=)
IL (2) IL259631B (https=)
RU (1) RU2708672C1 (https=)
WO (1) WO2017093993A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590862A (zh) * 2019-11-01 2019-12-20 南京师范大学 阿糖胞苷4-n位氨基酸衍生物及其制备方法与应用
CN112409431A (zh) * 2020-12-07 2021-02-26 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
CN115052607A (zh) * 2020-02-04 2022-09-13 拜欧赛特有限公司 天冬阿糖胞苷药物组合物和其用途
CN115461058A (zh) * 2020-04-23 2022-12-09 拜欧赛特有限公司 用于治疗血液癌的方法和方案

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US11104698B2 (en) 2015-12-03 2021-08-31 Biosight Ltd. Salts of conjugates for cancer therapy
WO2019012328A1 (en) * 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
KR20230074156A (ko) * 2020-09-21 2023-05-26 바이오사이트 리미티드 아스파시타라빈의 결정질 형태
JP2024540613A (ja) * 2021-11-21 2024-10-31 バイオサイト リミテッド がんの治療のためのシタラビン－アミノ酸系プロドラッグ
WO2023175622A1 (en) * 2022-03-17 2023-09-21 Biosight Ltd. Crystalline forms of aspacytarabine
WO2023228177A1 (en) * 2022-05-22 2023-11-30 Biosight Ltd. Compositions comprising aspacytarabine and additional compounds, and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275590A1 (en) * 2004-02-02 2011-11-10 BioSight Ltd., Conjugates for cancer therapy and diagnosis
CN103781760A (zh) * 2011-06-13 2014-05-07 株式会社Ihi 金属salen络合物化合物、局部麻醉药剂及抗恶性肿瘤药剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2949451A (en) 1959-04-21 1960-08-16 Hoffmann La Roche Preparation of thymidine and deoxyfluorouridine, and intermediates therefor
US3041335A (en) 1959-04-21 1962-06-26 Hoffmann La Roche Mercury salts of nitrogen heterocyclics and preparation thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4296105A (en) 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4348522A (en) 1980-01-23 1982-09-07 Starks Associates, Inc. N-(phosphonacetyl)-L-aspartic acid salts with piperazine, cyclohexylamine and calcium
EP0329184A3 (en) 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
RU2085557C1 (ru) 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP0737077A1 (en) * 1994-01-11 1996-10-16 Targetech, Inc. Hepatocyte-targeted drug conjugates
JP4157600B2 (ja) 1994-08-19 2008-10-01 ラ レフィオン バロンネ 化合物、製剤用組成物及びこれらを含む診断装置とこれらの利用
JPH0859688A (ja) 1994-08-25 1996-03-05 Mitsui Toatsu Chem Inc ５’−チオノエステル置換トリフルオロチミジン誘導体およびそれを有効成分とする制癌剤
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
PT1144011E (pt) 1998-12-11 2010-06-16 Coulter Pharm Inc Compostos pró-fármacos e processo para a sua preparação
JP5046219B2 (ja) 2002-10-31 2012-10-10 リガンド・ファーマシューティカルズ・インコーポレイテッド １，３−プロパン−１−アリールジオールの新規環状リン酸ジエステルおよびそのプロドラッグへの使用
KR101442288B1 (ko) 2006-12-13 2014-09-19 지보당 네덜란드 서비시즈 비.브이. 카복실산과 퓨린, 피리미딘, 뉴클레오사이드 또는 뉴클레오타이드의 향미 조절 유도체
CN101812105A (zh) 2009-02-25 2010-08-25 沈阳药科大学 阿糖胞苷5’-o-氨基酸酯和其盐类及其制备方法
KR20140079831A (ko) 2011-10-18 2014-06-27 아지노모토 가부시키가이샤 췌장암 및／또는 담도암 치료약
JP2016503005A (ja) * 2012-12-18 2016-02-01 ゴーダーヴァリ バイオリファイナリーズ リミテッド 腫瘍始原細胞を除去するための薬剤
WO2015178265A1 (ja) 2014-05-23 2015-11-26 日本化薬株式会社 新規なグルタミン酸誘導体およびその用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110275590A1 (en) * 2004-02-02 2011-11-10 BioSight Ltd., Conjugates for cancer therapy and diagnosis
CN103781760A (zh) * 2011-06-13 2014-05-07 株式会社Ihi 金属salen络合物化合物、局部麻醉药剂及抗恶性肿瘤药剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHEON EP, ET AL.: "Enhanced cellular uptake of ara-C via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells", 《JOURNAL OF PHARMACY AND PHARMACOLOGY》 *
CHHIKARA BS, ET AL.: "Development of cytarabine prodrugs and delivery systems for leukemia treatment", 《EXPERT OPINION ON DRUG DELIVERY》 *
FASINU P, ET AL.: "Diverse approaches for the enhancement of oral drug bioavailability", 《BIOPHARMACEUTICS DRUG DISPOSITION》 *
RENIS HE, ET AL.: "Antiviral activity of cytarabine in herpesvirus-infected rats", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590862A (zh) * 2019-11-01 2019-12-20 南京师范大学 阿糖胞苷4-n位氨基酸衍生物及其制备方法与应用
CN115052607A (zh) * 2020-02-04 2022-09-13 拜欧赛特有限公司 天冬阿糖胞苷药物组合物和其用途
CN115461058A (zh) * 2020-04-23 2022-12-09 拜欧赛特有限公司 用于治疗血液癌的方法和方案
CN112409431A (zh) * 2020-12-07 2021-02-26 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途

Also Published As

Publication number Publication date
IL287644A (en) 2021-12-01
US20180369265A1 (en) 2018-12-27
JP7149183B2 (ja) 2022-10-06
JP7417658B2 (ja) 2024-01-18
AU2016362830A1 (en) 2018-07-12
AU2022204373B2 (en) 2024-01-25
WO2017093993A1 (en) 2017-06-08
IL259631A (en) 2018-07-31
JP2018535989A (ja) 2018-12-06
EP3383407A4 (en) 2019-07-17
JP2022097619A (ja) 2022-06-30
RU2708672C1 (ru) 2019-12-11
US11058701B2 (en) 2021-07-13
CA3007058C (en) 2023-10-17
CA3007058A1 (en) 2017-06-08
IL259631B (en) 2021-10-31
EP3383407B1 (en) 2023-12-06
AU2022204373A1 (en) 2022-07-28
EP3383407A1 (en) 2018-10-10
JP2020183419A (ja) 2020-11-12
AU2016362830B2 (en) 2022-07-14
BR112018011177A2 (pt) 2018-11-21

Similar Documents

Publication Publication Date Title
AU2022204373B2 (en) Cytarabine conjugates for cancer therapy
CN110869029A (zh) 组合癌症治疗
US7173017B1 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US7893252B2 (en) Selectively depolymerized galactomannan polysaccharide
JP2011173928A (ja) 癌処置のためのエポチロンの使用
AU2927999A (en) Use of epothilones for the treatment of cancer
JP6223995B2 (ja) カンプトテシン類と抗癌効果増強剤の結合した高分子化合物及びその用途
CN114025766B (zh) 用于抑制gapdh的噁噻嗪化合物
EP0679160B1 (en) Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis
US12064445B2 (en) Cytarabine conjugates for cancer therapy
TWI727858B (zh) 維奈托克(venetoclax)之水溶性高分子衍生物
HK40025426A (en) Combination cancer therapy
HK1004484B (en) Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis
HK1067068A (en) Pyrimidine nucleotide precursors for treatment of inflammatory hepatitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180717